Details
Aromasin Indications
Adjuvant therapy in women with early invasive estrogen receptor-positive breast cancer in the postmenopausal period after 2-3 years of initial adjuvant tamoxifen therapy.
Treatment of advanced breast cancer in women with natural or induced postmenopausal status who have progressed after antiestrogen therapy. No efficacy has been demonstrated in patients with a negative estrogen receptor test.
Contradictions
Aromasin is contraindicated in patients with known hypersensitivity to the active ingredient of the drug or to any other component of the drug listed in the "Composition". The drug is also contraindicated in premenopausal women, women during pregnancy or breastfeeding.
Dosage & Administration
Aromasin is recommended to take 25 mg once a day, preferably after meals.
In patients with early-stage breast cancer, treatment with Aromasin should be continued until the completion of five years of combination sequential adjuvant hormone therapy (continuation of Aromasin therapy after tamoxifen) or until tumor recurrence occurs.
In patients with advanced breast cancer, treatment with Aromasin should be continued until tumor progression is evident.
No dose adjustment is required in patients with hepatic or renal impairment
